Warning letter
Chase Medical, Inc.: warning letter of Oct 9, 2001
FDA warning letter UCM178395 · Dallas District Office
Key facts
| Reference number | UCM178395 |
|---|---|
| Company | Chase Medical, Inc. |
| Subject | CGMP Requirements of the Quality System Regulations/Adulterated/Misbranded |
| Issue date | Oct 9, 2001 |
| Posted date | Oct 9, 2001 |
| Issuing office | Dallas District Office |
| Product type | Devices |
| CFR sections cited | 806, 820, 806.2(i), 806.10(a), 803.50 |
| Country | 3 |
| Inspection city | Richardson |
| Inspection ZIP | 75081-2270 |
| Inspection start date | Aug 6, 2001 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: